News & Events

August 30, 2016 –

Trinity Partners publishes article "Burden of illness for super-refractory status epilepticus patients"

 

See the full text HERE

June 3, 2016 –

Partner Ryan P. Million, Ph.D. authors a White Paper discussing oncology pricing in advance of ASCO this week.  

 

See the full text HERE

May 20, 2016 –

Trinity Partners to Present on Alzheimer’s Predictors at ISPOR Annual Meeting

 

Trinity Partners, a leading global life sciences consulting firm, today announced it will participate in ISPOR’s 21st Annual International Meeting, May 21-25, in Washington, D.C.

This year’s International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting is designed to bring together thought leaders in health research related to clinical, economic and patient reported outcomes, health policy and patient preferences, and provide an update on how health care systems from around the world are applying real-world data to make real-world decisions.
“Trinity’s philosophy is to provide clients with innovative analyses that produce robust evidence and strategic insights and enable them to make important decisions in today’s dynamic and ever-changing healthcare industry,” said Jillian Godfrey Scaife, Principal, Trinity Partners. “We look forward to attending ISPOR, connecting with members of the pharmaceutical community and showcasing Trinity’s dynamic outcomes research initiatives.”

Trinity experts will participate in a poster presentation at ISPOR:

Finding Potential Predictors of Alzheimer’s Disease Using Medicare Claims Data (May 23, 8:30 – 2:00 p.m.) Gavin Miyasato, associate director of statistics, and Gretchen Chiu, statistician, will present a poster discussing the potential predictors of Alzheimer’s Disease using longitudinal data captured in Medicare claims data.
For more information on Trinity Partners, please visit http://www.trinitypartners.com/ or follow Trinity on Twitter: https://twitter.com/TrinityLifeSci.

May 5, 2016 –

Trinity Partners Continues Investment in Primary Market Research Group with New Engagement Manager 

 

Trinity Partners, a global life sciences consulting firm, announced today that it has welcomed Steve Yonish as an Engagement Manager in its Primary Market Research (PMR) Group. In this new role, Steve will lead engagements for biopharmaceutical clients on topics ranging from market access and reimbursement, pharmaceutical pricing, market/opportunity assessment, brand positioning and more. He will also be responsible for helping to grow Trinity’s Princeton, New Jersey office, which will position Trinity in close proximity to many long-standing clients and will officially open in Summer 2016.

Prior to joining Trinity, Steve was an Associate Partner with BluePrint Research Group where he made significant contributions to business development and led engagements for large-scale global qualitative and quantitative projects across a broad range of therapeutic categories. In addition to his time at BluePrint, Steve has almost twenty years of experience in consultative market research including manufacturing experience with Bristol-Myers Squibb, and market research leadership roles at BioVid Corporation, The Zitter Group, The Monitor Group and Forrester Research. Steve received his BA from Cornell University in Economics, and later received a Ph.D. from the University of Wisconsin in Political Science.

“Steve’s deep industry experience and proven track record of leading strategic initiatives that address a broad range of issues that our clients face make him a perfect addition to our team,” said Neal Dunn, Partner at Trinity Partners. “His hire represents our continued attention to our clients’ primary research needs.”

“I am inspired by the dynamic work that the Primary Market Research group is doing here at Trinity Partners, and I look forward to sharing the knowledge I’ve gained during my time in this industry and collaborating with this talented team.”

Steve’s hire is one of many for Trinity over the past couple of months. Based just outside of Boston, Trinity has over 100 employees with offices in San Francisco and New York City, and was recently named to Consulting Magazine’s list of Fastest Growing Firms as well as The Boston Business Journal’s ‘Best Places to Work’ list. In addition to his regular roles and responsibilities, Steve will participate in the company’s traditional commitment to the development of its young professionals, serving as a mentor to junior colleagues to help improve their writing and strategic thinking skills.
# # #
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click HERE.

May 2, 2016 –

Trinity Partners to Exhibit at PMRG CONNECT

 

Trinity Partners, a leading global life sciences consulting firm, today announced it is participating in PMRG's 2016 Healthcare Marketing Researchers CONNECT, May 1-3, in National Harbor, Maryland, booth #55.

PMRG CONNECT is designed to bring together leaders in pharmaceutical, biotechnology and medical device marketing research and provide an update on how changes to the healthcare landscape affect framing and prioritization of key business issues and new data tools and techniques.

“Trinity has a deep expertise conducting strategic market research that includes pricing, segmentation, forecasting, positioning, optimization and tracking studies to support all stages of the brand lifecycle,” said Neal Dunn, Partner, Trinity Partners. “We look forward to attending PMRG CONNECT, speaking with members of the pharmaceutical community and showcasing Trinity’s dynamic market research initiatives.”

As an adviser to 18 of the top 25 biopharmaceutical companies, Trinity is well-equipped to address changes to the ever-evolving healthcare industry. With unrivaled capabilities, access to a wealth of critical stakeholders and a cutting-edge mix of research techniques, Trinity is uniquely positioned to inform the strategy and tactics at each stage of the brand planning process and uncover not only what will happen in the future, but the factors that drive that outcome.

For more information on Trinity Partners, please visit http://www.trinitypartners.com/ or stop by booth #55 during PMRG CONNECT.
# # #
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here.

April 22, 2016 –

Trinity Partners named to the Boston Business Journal’s annual ‘Best Places to Work’ List

 

Trinity Partners, a global life sciences consulting firm, is very pleased to announce that it has been selected as a 2016 best place to work by the Boston Business Journal. Trinity has been included in the medium-sized company category (100 to 249 employees) on the annual list, which is determined each year based on survey responses provided by employees. To see the full list, click here: http://www.bizjournals.com/boston/news/2016/04/19/bbj-announces-the-2016-best-places-to-work.html

Interested in joining our dynamic and growing team? Please contact Courtney DeMaio at cdemaio@trinitypartners.com or Lisa Burke at lburke@trinitypartners.com

2016_BPTW_sq_2501.png

April 13, 2016 –

Trinity Partners To Attend 2016 Annual PMSA Conference

 

Trinity Partners, a global life sciences consulting firm, today announced that several employees from the Advanced Analytics group will be attending 2016 PMSA Conference, taking place in Las Vegas, NV, April 17 – 20.
Sponsored each year by the Pharmaceutical Management Science Association, this year’s conference is titled “Game-Changing Analytics: The Odds Are In Your Favor”, and will feature presentations from thought leaders across the pharmaceutical industry on various topics related to forecasting, data-driven medicine, and more. Trinity’s Director of Advanced Analytics, Todd Foster, and Engagement Manager, Kevin Francis will attend.
“At Trinity we have a deep understanding of the need for life sciences companies to harness data to help inform their business strategies, and we pride ourselves in providing comprehensive analytical support for our clients across the industry,” said Todd Foster. “We look forward to the opportunity to discuss best practices and new approaches with our peers and clients during the conference with the intention of inspiring new strategies to arm our clients with the highest level of insights possible.”
For more information about Trinity Partners, please visit www.trinitypartners.com. To schedule a meeting to meet with a Trinity executive during the show, please contact Kathryn McMahon at kmcmahon@pancomm.com.

 

To learn more about our advanced analytics capabilities, click HERE

April 5, 2016 –

Trinity Partners Expands Primary Market Research Group with Strategic Hires 

 

Trinity Partners, a global life sciences consulting firm, announced today that it has welcomed three new consultants to its Primary Market Research (PMR) Group. Each new hire brings at least five plus years in the consulting space:

• Irana Abibova, has joined the firm with more than ten years of experience in PMR and brand strategy. She comes most recently from the Optimal Strategix Group.
• Kyle Martin, who comes from RG+A, brings experience in aspects of qualitative and quantitative research with proven ability in all phases of the research cycle: design, gather, analyze and report.
• Kevin Hisler joins the firm from The Research Partnership, Inc. where he was a research manager.

“In today’s competitive healthcare landscape, it is crucial that pharmaceutical companies position their products for market success,” said Neal Dunn, Partner at Trinity Partners. “Our continued investment into Primary Research is a reflection of that need, and we have built considerable expertise in conducting strategic market research that includes pricing, segmentation, forecasting, positioning, optimization and tracking studies to support all stages of the brand life cycle.”

These hires are a few of many for Trinity in recent months. Based just outside of Boston, Trinity has more than 100 employees with offices in San Francisco and New York City, and was recently named to Consulting Magazine’s list of Fastest Growing Firms. The company is devoted to fostering employee growth and development and implementing the tools and initiatives needed to drive business success. In addition to their regular roles and responsibilities, each of the new consultants will participate in the company’s traditional commitment to the development of its young professionals, serving as a mentor to junior colleagues.

April 1, 2016 –

Trinity Managing Partner Dave Fitzhenry discusses breakthrough innovations in the April issue of PharmaVOICE

 

Read more HERE.

March 31, 2016 –

Trinity Partners Furthers Investment in Talent with New Hires 

 

Trinity Partners, a global life sciences consulting firm, announced today that as part of their effort to recruit and maintain top talent, the company has hired Lisa Burke as the Director of Recruiting, a role that is new to the company. The company also announced that they have hired Amy McCormack as the new Director of Talent. Both new hires are located in Trinity’s Waltham headquarters.

Lisa and Amy both bring to Trinity Partners 15+ years of experience with working talent in the Consulting space. Prior to Trinity, Lisa was the Global Executive Recruiting Leader for the Advanced Strategic Analytics Team at Boston Consulting Group. She has also worked with Hitachi Consulting, Accenture and Cognizant Technology Solutions, amongst other firms. In this new role, she will be responsible for recruiting the strongest talent to enhance and build Trinity’s industry expertise and to meet and support clients’ growing needs. Lisa received her BA from the University of Maryland and has received training in executive leadership from Stanford Business School.

Amy, who will be responsible for advancing firm-wide professional development, worked as a talent development and resourcing manager at Beacon Partners prior to joining Trinity Partners. In her past role, she oversaw the design, growth and implementation of training and development initiatives and programs supporting the company’s core departments. Amy has also held roles at other consulting firms, including Bain Capital, PriceWaterhouseCoopers and Deloitte. She received her BA from the University of Hartford.

“Recruiting and retaining top talent is crucial for our business, and throughout our almost twenty years we have maintained a steadfast commitment to the development of professionals who are the engines that drive our innovation and insight,” said Dave Fitzhenry, Managing Partner. “Both Lisa and Amy have strong track records in the talent acquisition and management space, respectively, and we look forward to continuing to meet evolving client needs while building an environment where multiple generations of workers are satisfied and successful.”

Both hires reflect the company’s continued growth over the past few months. Based just outside of Boston, Trinity has more than 100 employees with satellite offices in San Francisco and New York City, and was recently named to Consulting Magazine’s list of Fastest Growing Firms . The company is devoted to fostering employee growth and development and implementing the tools and initiatives needed to drive business success.
# # #
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here: [http://www.trinitypartners.com/index.php/our-team/our-partners/]


Media Contact
Kathryn McMahon
PAN Communications
kmcmahon@pancomm.com
617-502-4300

March 29, 2016 –

Partner Ryan Million, PhD Quoted in Medical Marketing & Media

 

Trinity Partners’ Ryan Million was quoted in the latest issue of Medical Marketing & Media. Dr. Million’s comments were featured in an article titled “Drugmakers move to counteract expiring patents with new respiratory drugs”. In the article, Dr. Million discusses trends in the development of treatments for orphan and specialty respiratory diseases. To read the full article, please click here.

To learn more about Dr. Million and our full leadership team, click here.

February 29, 2016 –

In a new article for PM360, Trinity's own Herman Sanchez, Nandini Hadker and Gavin Miyasoto discuss how pharma companies can anticipate and effectively address market access and adoption challenges

 

Click HERE to read the article.

February 24, 2016 –

Neal Dunn sat down with MM&M to answer pressing questions around orphan drug development

 

Did you know 30 million Americans are afflicted with a rare disease? Neal Dunn sat down with MM&M to answer pressing questions around orphan drug development. Click HERE for article.

January 15, 2016 –

Trinity Partner's Natasha Udpa and Ryan Million have published an article in the December issue of Nature

 

With global sales of more than $50 billion, monoclonal antibody therapeutics are starting to face competition from biosimilar entrants. Read more in Nature by clicking HERE.

January 12, 2016 –

Trinity Partners, a global life sciences consulting firm, today announced that several of its partners will attend the 34th Annual JP Morgan Healthcare Conference taking place in San Francisco, CA, January 11th – 14th

 

One of the largest meetings in the industry, the annual J.P. Morgan Healthcare Conference brings together global industry leaders, emerging fast-growth companies, innovative technology creators, globally minded service providers, and members of the investment community. This year more than more than 4,000 investors are expected to attend.

"The J.P. Morgan Healthcare Conference offers a unique opportunity for companies across the healthcare sector, including many of our clients, to present on and discuss emerging trends in this ever-evolving industry," said Ryan Million, PhD, Partner at Trinity Partners. "As in years past, we look forward to engaging in conversations with clients and other industry leaders around best practices for navigating the complex drug development market, with the ultimate goal of improving lives for patients.”

For more information about Trinity Partners, please visit www.trinitypartners.com. To schedule a meeting to meet with a Trinity executive during the show, please contact:

 

Contact Information

Kathryn McMahon

617-502-4357

kmcmahon@pancomm.com

January 11, 2016 -

Trinity Partners Unveils 2016 Predictions for the Biopharmaceutical Industry -  Drug pricing, M&A, Gene Editing and Precision Medicine Will Be Key Focus Areas 


Trinity Partners, a global life sciences consulting firm, today issued its healthcare predictions for 2016.

 

  1. Drug pricing and biosimilars in light of the upcoming Presidential election:

Thanks to recent media uproar around companies like Turing Pharmaceuticals, the company that upped the price of a life-saving drug for parasitic infection by 5,000 percent, drug pricing is expected to be a huge topic around the presidential election over the next year with candidates sharing proposals to help address this issue. This will also likely bring continued attention to biosimilars, which are drugs designed to have properties similar to biologics that have previously been approved. In the next year, close attention will be paid to their rate of adoption in the US compared to the past uptake of generics, especially given obstacles such as pricing, strict regulations and questions around marketing.

  1. The revenge of the DTC ad:

As it becomes more and more important to prove a drug’s worth, pharmaceutical companies are increasingly pouring money into Direct-to-Consumer ads. For example, Biogen recently announced 800 new layoffs in order to shift that money towards MS patient programs. However, this type of investment may bring on controversy in 2016. Physicians have mixed feelings on DTC ads, and the American Medical Association recently voted for a ban on all direct-to-consumer advertising for drugs and medical devices from their publications.

  1. Business Models will continue to change:

Deal making M&A will stay at a high level in 2016 thanks, in some part, to inversion. Companies such as Pfizer are moving their addresses to Ireland where the corporate tax rate is only 12.5%. Acquisitions of biotechs will also be an interesting space to watch in 2016, especially in terms of valuations. In 2015, companies that drove up their own price have ended up in hot water, so the return to more rational pricing for deals is imminent in 2016.

  1. Pharma companies will look to unlock the potential of gene editing:

In 2016, the rise of gene editing will continue. But the question of how businesses can take advantage will be at the forefront; specifically as it progresses from being a research/screening tool to one that promises important applications in drug development, cell therapy and bioprocessing.

  1. Precision Medicine momentum will continue:

The momentum that began with President Obama’s 2015 Precision Medicine Initiative will continue into 2016 thanks to a $215 million investment in the President’s 2016 budget. The investment raises hopes of providing drug developers with greater insights into the biological, environmental, and behavioral influences on diseases. 

About Trinity Partners

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here: [http://www.trinitypartners.com/index.php/our-team/our-partners/]

October 29, 2015 -

Trinity Partners Recognized for Key Industry Insights at AMCP Nexus 2015 Conference -  Company thought leaders awarded silver medal for their poster on the prevalence of Alzheimer’s Disease among the Medicare population 


Trinity Partners, a global life sciences consulting firm, today announced that several of its experts are presenting on timely issues related to managed care at the Academy of Managed Care Pharmacy (AMCP) Nexus 2015 conference being held this week in Orlando, FL.

A Trinity poster, authored by employees Gretchen Chiu, Zheng Wang, Gavin Miyasato, David Small, and Jillian Scaife, was awarded a silver medal. Titled, “An Investigation of the Prevalence of Alzheimer’s Disease, Diagnostic Screening Rates and Associated Healthcare Costs and Resource Utilization Among the Medicare Population,” the poster examines the prevalence, screening rates, and average cost of Alzheimer’s Disease (AD) and AD Related Dementia (ADRD) patients using 2010-2013 Medicare data. 

This year’s AMCP conference focuses on issues and challenges faced by managed care professionals looking to improve outcomes and reduce spending on diseases such as AD. Topics being examined include specialty pharmacy management, the changing healthcare environment, practical applications of managed care pharmacy research, and more.

“Alzheimer’s disease is highly prevalent among the aging population and is associated with very high medical costs. We are pleased to have the opportunity to assess how changes in diagnostic screening practices and treatment paradigm could have a significant impact on the cost of the AD and AD/ADRD population to Medicare” said Nandini Hadker, Engagement Manager at Trinity Partners.   

Gretchen Chiu, Statistician and lead author of the poster added, “It is rewarding to be recognized by our peers at the AMCP for the work that we are doing in this important disease space.”

For more information about Trinity Partners, please visit www.trinitypartners.com.

October 27, 2015 -

Trinity Partners Expands Primary Market Research Group with Strategic Hire  - Company Taps PhD Nason Russ to Dive Further into Patient Insights


Trinity Partners, a global life sciences consulting firm, announced today that it has welcomed Nason Russ, PhD, as a Senior Consultant in its Primary Market Research (PMR) Group. In this new role, Nason will help biopharmaceutical clients to characterize buying processes and treatment landscapes, employing projective techniques to uncover underlying drivers of behavior.

Nason brings Trinity diverse industry experience with Fortune 500 and multi-national organizations spanning a range of industries. Prior to joining Trinity, Nason was a Senior Consultant at C1 Consulting where he worked closely with pharma and biotech clients to help them value and prioritize market opportunities and launch new brands. Before that he worked at Roger Green & Associates, TNS Global, and Hase Schannen Research Associates after beginning his career at The Vanderveer Group.  Nason received his BA in psychology from Rutgers University, and went on to receive his PhD in clinical psychology from Virginia Tech.

“Nason’s background in clinical psych provides him with a unique ability to facilitate discussions with all key stakeholders, garnering insights beyond that of a typical moderator,” said Aparna Deshpande, Principal at Trinity Partners. “This is a particularly important skill since his interviews gather deeper and more relevant insights into not just clinical and rational behaviors but the underlying emotional drivers behind behaviors.”

A pharmaceutical executive who recently worked with Nason highlighted his diligence in client services as going above and beyond experiences with other market researchers.  Calling him a true strategic partner, the executive also cited his ability to probe and go beneath the surface of respondent testimonials, thereby enabling the broader team to derive deeper insights.

“One of the things I enjoy most about market research is the opportunity to understand how people think, the underlying ‘whys’ that drive their behavior, and then translating that into strategic insights to address client’s business questions,” said Nason.  “I look forward to further pursing this passion at Trinity Partners.” 

Nason’s hire is one of many for Trinity over the past couple of months. Based just outside of Boston, Trinity has over 100 employees, with satellite offices in San Francisco and New York City. In addition to his regular roles and responsibilities, Nason will participate in the company’s traditional commitment to the development of its young professionals, serving as a mentor to junior colleagues to help improve their writing and strategic thinking skills. 

September 17, 2015 -

Trinity Publishes Article in Applied Clinical Trials

 

Principal Jillian Scaife and Consultant Nick Simmons-Stern have authored an article recently published in Applied Clinical Trials titled: Designing Alzheimer’s Disease Clinical Trials For Success.  With an aging population, no current cure, and great costs of care, Alzheimer’s disease continues to pose significant public health concerns.  Recent estimates suggest that 28 million Americans will develop the disease by 2050.  Pharmaceutical companies are investing millions of dollars into Alzheimer’s disease research, but without careful clinical trial design, even the most promising drugs can fail.    This article reviews core considerations of two critical components of Alzheimer’s trial design – sample enrichment and outcomes selection.   Specifically, the article examines the role of diagnostic imaging and innovative cognitive and functional measures in cultivating successful Alzheimer’s disease treatments.

Jillian Scaife is a graduate of Princeton University, where she received her degree in Molecular Biology.  Jillian received her MPH degree from the Johns Hopkins Bloomberg School of Public Health.  She received an MBA from the F. W. Olin Graduate School of Business at Babson College.  Nick graduated cum laude from Yale University, where he earned a BA with honors in Cognitive Science.

Click here to read the full article.

September 11, 2015 -

Trinity Publishes Article in Nature Reviews

 

Partner Ryan Million, PhD and Consultant Rachel Chizkov recently published an article titled: Trends in breakthrough therapy designation. Breakthrough therapy designation was established by the FDA 3 years ago to help speed the review of products that treat serious medical conditions and unmet medical needs. The article examines whether this relatively new designation affects competition within various markets and its future outlook.

The article is available for purchase through Nature’s website, here. To learn more about Dr. Ryan Million and our other partners, click here.

August 14, 2015 -

Trinity Partners Announces Fourteen New Hires From the Class of 2015

 

Trinity Partners, a global life sciences consulting firm, announced today that it has welcomed its 19th annual class of recent graduates, on boarding 14 new hires from the class of 2015. Hailing from top universities across the nation including Harvard, Yale, Swarthmore, Williams, Princeton, Dartmouth and the University of Mississippi, these new additions to the company will join various practices of the business, including General Consulting, Advanced Analytics and Primary Market Research.

As part of the on boarding process, Trinity provides training and mentoring on core consulting skills for the life sciences industry. Facilitated by more than 30 members of the company who have a wealth of expertise in the industry, training focuses on understanding Trinity’s unique business model as well as developing key technical, analytical and communication skills that have immediate application to project work. Trinity also provides new hires the opportunity to work with a peer mentor who serves as a resource for questions related to project work, technical skills and integrating into the culture. Additionally, new hires review recent case studies as part of a capstone project where they present new, innovative ideas and solutions around previously conducted work.

“Creating a clear career path with proper development, training and mentorship is essential for attracting and retaining the next generation of life science leaders,” said Michelle Adams, Director of Talent, Trinity Partners. “Each year we welcome a new class of recent college graduates to dive head first into a fast-paced and challenging work environment, while providing the tools that they need to learn as they go. It’s a win-win for Trinity Partners, our clients, and for our new recruits.”

This group of new hires, one of the largest in recent years, reflects Trinity’s continued growth, expanded client base, and broadening influence in the life sciences industry. Based just outside of Boston, Trinity has over 100 employees with offices in San Francisco and New York City. The company maintains an unwavering commitment to the development of its professionals who are the engines that drive its innovation and insight. Trinity will celebrate its 20th year in business in 2016.

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here: [http://www.trinitypartners.com/index.php/our-team/our-partners/]

July 17, 2015 -

Team from Trinity Collaborates on Article Published in Clinical Epidemiology

 

Partner Ryan Million, with a team from Trinity Partners, along with Amgen and Wade Outcomes Research and Consulting have published an article in Clinical Epidemiology.  The article, titled: Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States, discusses the results of a study undertaken to estimate the prevalence of bone metastases from solid tumors and to describe recent trends in the use of BTA in the United States.  The study concluded that of the estimated 333,000 solid tumor patients living with bone metastases in the US in 2012, many may have received less than optimal care to prevent bone complications during the calendar year.

In addition to Dr. Million, the team from Trinity Partners who contributed to the article were: Kevin Francis, Avanti Adhia, and Hasmik Alvrtsyan.

To view the full text of the article, please visit: http://www.dovepress.com/prevalence-of-bone-metastases-and-bone-targeting-agent-use-among-solid-peer-reviewed-fulltext-article-CLEP#

To learn more about Dr. Ryan Million, and our other partners, please click here 

To see our other publications, please click here 

June 9, 2015 –

Trinity Partners Co-sponsors Panel Discussing Impact of Biosimilars on the Future of Affordable Medicine

Panel to address the regulatory and commercial challenges posed by this innovation pathway

Trinity Partners, a global life sciences consulting firm, today announced it is co-sponsoring a panel bringing together diverse perspectives from the life sciences ecosystem to discuss how biosimilars differ from generic products, FDA regulations and the cost of developing a biosimilar, and the implications for pharma, physicians and patients.


Sponsored by the Healthcare Businesswomen’s Association (HBA), the event will take place Wednesday, June 10 from 5:30- 8:30 p.m., EDT, at the Genzyme headquarters in Cambridge, MA.
Marie Sanchirico, director of Medical Managed Care at Genzyme, A Sanofi Company, will moderate the panel. Additional panelists include:


• Susan Dexter, principal consultant, Latham Biopharm
• Magdalena Leszcyniecka, president and CEO, STC Biologics, Inc
• Michael Wyand, chief technology officer, EPIRUS Biopharmaceuticals


“Changing regulations and a looming biotech patent cliff have created significant opportunity for biosimilars to boom in the global market over the next few years,” said Jillian Godfrey Scaife, Principal, Trinity Partners. “We look forward to hearing insights from industry leaders about this important new pathway and how it could revolutionize cost-effective healthcare.”


To learn more about the panel or if you are interested in attending, please visit: https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=4A3AFD7A-3EF8-E411-B471-0050569C00A7

May 15th, 2015 –

Trinity Partners Experts Share Key Industry Insights at ISPOR 20th Annual Meeting

Company thought leaders to address current issues driving change across today’s healthcare landscape

Trinity Partners, a global life sciences consulting firm, today announced several of its experts will present on timely issues in healthcare at the 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference, May 16-20 in Philadelphia, PA.
“It is rewarding to share key insights gleaned through our work with clients who are on the front lines of developing innovative treatments that can dramatically improve the lives of patients.”
This year’s conference examines the integration of big data, patient data and cost-effectiveness into clinical practice. As the adviser to 18 of the top 25 biopharmaceutical companies, Trinity is uniquely positioned to address changes reshaping the healthcare industry. Company experts will specifically discuss topics such as healthcare resource utilization and the burden of illness within specific therapeutic areas including diabetes, Acute Myeloid Leukemia (AML), COPD and hospital-acquired infective endocarditis.
“Healthcare is changing rapidly and we are pleased to have the opportunity to present and discuss such important topics with leaders from across the industry,” said Jillian Godfrey Scaife, Principal, Trinity Partners. “It is rewarding to share key insights gleaned through our work with clients who are on the front lines of developing innovative treatments that can dramatically improve the lives of patients.”
In addition to a podium presentation on healthcare resource utilization among Medicare beneficiaries with COPD, Trinity will also present three posters during the conference. Please see more information on all four presentations below:

Podium Presentation:
• Title: Health Care Resource Utilization Among Medicare Beneficiaries with COPD: Comparison of High and Low Users
Date and time: Monday, May 18, 3:45-4 p.m. ET
Location: Philadelphia Marriott Hotel, Grand Ballroom, Salon C, D, E (Level 5)
Poster Presentations:
• Title: Real-world Canagliflozin Utilization: Impact on Glycemic Control in Patients with Type 2 Diabetes Mellitus
Date and time: Monday, May 18, 8:30-2:15 p.m. ET (display hours), author discussion 1:15-2:15 p.m.
Location: Philadelphia Marriott Hotel, Franklin Hall, N15
• Title: The Burden of AML within the Date and time: Tuesday, May 19, 3:45-7:45 p.m. ET (display hours), author discussion 6:45-7:45 p.m.
Location: Philadelphia Marriott Hotel, Franklin Hall, A11
• Title: Examination of Hospital-acquired Infective Endocarditis Using Medicare Claims Data
Date and time: Tuesday, May 19, 3:45-7:45 p.m. ET (display hours), author discussion 6:45-7:45 p.m.
Location: Philadelphia Marriott Hotel, Franklin Hall, N4

For more information about Trinity Partners, please visit www.trinitypartners.com or stop by Tabletop 1 during the meeting. Information about ISPOR can be found here: http://www.ispor.org/event/index/2015philadelphia

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here: [http://www.trinitypartners.com/index.php/our-team/our-partners/]

Contacts
PAN Communications
Kathryn McMahon, 617-502-4327
kmcmahon@pancomm.com

July 31, 2014 –

Partner Ryan Million Publishes Article on Specialty Pharma Business Model in Pharmaceutical Executive


In this article, Dr. Million identifies several challenges for companies pursuing drug development in specialty therapeutic areas.  A review of the market environment revealed three critical obstacles facing these companies:  increased competition; finding patients who benefit from these treatments, and market access.  Dr. Million explores these challenges and looks at the ways in which the pharmaceutical industry is responding.  He also suggests approaches to help companies overcome these hurdles to better navigate the specialty pharma landscape.

Jillian Scaife, Principal at Trinity Partners, and Emily O’Connor, Senior Manager at Amgen, also contributed to this article. 

To read the full article, click here: Pharma_Exec_June_2014.pdf

To learn more about Dr. Ryan Million and our other partners, click here 

To learn more about Jillian Scaife and our other principals, click here

June 30, 2014 –

The Value of Specialty Pharmaceuticals - A Systematic Review, Published in the American Journal of Managed Care

 

Trinity Partners is pleased to announce the publication of “The Value of Specialty Pharmaceuticals – A Systematic Review” in the American Journal of Managed Care (AJMC).  The manuscript, published in the June edition, is the result of a collaboration between Trinity Partners, the National Pharmaceutical Council (NPC), and the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center.

 

Authors: Martin Zalesak, MD, PhD; Joyce S. Greenbaum, BA; Joshua T. Cohen, PhD; Fotios Kokkotos, PhD; Adam Lustig, MS; Peter J. Neumann, ScD; Daryl Pritchard, PhD; Jeffrey Stewart, BA; and Robert W. Dubois, MD, PhD

 

Background: Specialty pharmaceuticals (typically biological therapies which may cost tens of thousands of dollars for a single course of treatment) hold promise for patients living with complex and chronic conditions.  However, high research and development costs, special handling, and other necessary enhancements to patient support programs all contribute to frequently higher prices for these products. This study sought to assess the value of specialty pharmaceuticals through an examination of the clinical, functional, and economic benefits of these treatments for the top three disease areas by pharmaceutical spend: rheumatoid arthritis (RA), multiple sclerosis (MS), and breast cancer (BC). 

Key Findings:

  • Specialty pharmaceuticals can offer significant benefits to patients living with complex and chronic conditions compared with previously available therapies.

  • In rheumatoid arthritis patients, the introduction of biologics cost-effectively improved clinical and functional outcomes compared with traditional disease-modifying antirheumatic drugs.

  • In multiple sclerosis patients, this review indicates biologic therapies are clinically effective, as all studies reviewed reported a reduction in the relapse rate. Functional studies provided neutral findings.

  • In breast cancer patients, the majority of articles reviewed yielded statistically inconclusive results for survival. With respect to the functional metric, the results were strongly favorable, indicating that specialty pharmaceuticals improve quality of life.

 

Conclusions:Our review of the three largest specialty pharmaceutical categories suggests that these novel therapies hold promise for arresting disease progression and improving quality of life.  These findings are subject to limitations, including gaps in the literature we reviewed and our need to focus on only the most salient measures of drug performance.  Nonetheless, these findings raise the possibility that specialty pharmaceuticals for other disease areas might likewise confer substantial patient benefit.  

To read the full article, click HERE

June 12, 2014 –

Trinity Partners Among Finalists for ISPOR’s “Best Poster Research Presentation” Award


Trinity’s Poster, Medicare Hepatitis C Patients: Are patients under 65 different?,  was chosen as a finalist for the “Best Poster Research Presentation” award at last week’s 19th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting.  The top 10% of scores given by the Contributed Research Review Committee at the time of submission are considered for this award.

This study sought to assess how Medicare Hepatitis C (HCV) patients under 65 years of age differ from those more than 65 years of age, and whether age influences the cost of care for those patients. The team found that Medicare HCV patients under 65 years of age are more expensive to treat, but that age was not necessarily the factor contributing to the increase in cost.  Instead, the increased cost appears to be due to higher rates of disability, end stage renal disease, and comorbidities existing in the younger population.

Poster authors: Lisa M. Meckley, Zheng Wang, Gavin Miyasato, Jillian Scaife, Herman Sanchez

View the poster to learn more.

May 28, 2014 -

New White Paper from Trinity Partners Examines U.S. Payer Expectations

 

Trinity Partners is pleased to release a new white paper – Demystifying the U.S. Payer Mindset and Expectations. Spurred by conversations with their clients in the biotech and pharmaceutical industry, Trinity sought to explore some of the questions they hear most often from manufactures around payers’ perspectives and needs including:

  • What keeps payers up at night?
  • What evidence do payers ultimately want to see in order to provide favorable access and reimbursement?
  • What are best practices in manufacturer-payer collaboration as seen from the point of view of payers?

To explore these, and other questions, Trinity conducted quantitative and qualitative market research with U.S. Payers, both commercial plan directors and advisors to the Centers for Medicare and Medicaid Services (CMS). Trinity’s research confirmed some of the anecdotally supported opinions around the manufacturer-payer relationship, but also brought an enhanced level of understanding and deeper insights into the way manufactures and payers interact.  

Link to Whitepaper

May 19, 2014 -

Trinity to Attend 19th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting in Montreal from May 31st to June 4th.

 

Please visit us at Table (T2) for a copy of our recent study - Demystifying the U.S. Payer Mindset and Expectations, free giveaways, plus the chance to win an iPad.   Our team is also pleased to be presenting four posters which highlight our spectrum of HEOR capabilities and expertise.

See our ad in this year's ISPOR exhibitors' booklet.